December 03, 2015
1 min read

FDA accepts NDA for review of Viekira Pak

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

AbbVie announced that the FDA has accepted its New Drug Application for review of Viekira Pak for the treatment of chronic hepatitis C virus infection, including those with compensated cirrhosis.

A combination of ombitasvir, paritaprevir and ritonavir tablets with dasabuvir tablets, Viekira Pak, (AbbVie) can be used with or without ribavirin, but is not recommended for patients with decompensated cirrhosis. The proposed dosing in the NDA is three oral tablets once daily with a meal, with or without twice-daily ribavirin. Viekira Pak is currently taken twice daily as three tablets in the morning and one tablet in the evening, taken with a meal, according to the release.

“Nearly one year after the launch of Viekira Pak, AbbVie is pleased to announce the acceptance of a New Drug Application for a once-daily formulation for the treatment of patients with chronic genotype 1 hepatitis C,” Michael Severino, MD, executive vice president, research and development and chief scientific officer at AbbVie, said in the release. “This milestone further underscores AbbVie's commitment to offer people living with hepatitis C optimized treatment options.”

In October, the FDA issued a report, warning that the fixed-dose combination could lead to severe liver injury and required AbbVie to update the drug label. In a previous interview, Barry Bernstein, MD, vice president, infectious disease development, AbbVie, told that the label updates were “based on postmarketing reports” and the company was in compliance with the FDA’s requests.

The FDA first approved Viekira Pak for the treatment of HCV in December 2014.

Disclosures: Severino is employed by AbbVie.